Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02747004 · ClinicalTrials.gov registry record · Phase 2
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
A Phase 2 study of Metastatic Breast Cancer, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 2
- Development phase
- 234
- Enrollment target
- 20
- Study locations
NCT02747004 is a Phase 2 study of Metastatic Breast Cancer that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 234 participants, above the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT02747004, a Phase 2 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 234 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Abemaciclib
- DRUG Prophylactic Loperamide
Study Locations (20)
Other
- Sanatorio Parque - Salta
- AKH - Vienna
- Grand Hopital de Charleroi-Site Notre-Dame - Charleroi
- Centre Hospitalier Universitaire Sart Tilman - Liège
Oost-Vlaanderen
- Universitair Ziekenhuis Gent - Ghent
- VITAZ - Sint-Niklaas
Arizona
- The University of Arizona Cancer Center - Tucson
New Hampshire
- Dartmouth Hitchcock Medical Center - Lebanon
Tennessee
- Tennessee Oncology PLLC - Nashville
Texas
- The Center for Cancer and Blood Disorders - Fort Worth
Wisconsin
- University of Wisconsin Clinical Research Center - Madison
Buenos Aires
- CENIT Centro de Neurociencias, Investigación y Tratamiento - CABA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2016-09-14 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02747004
The ClinicalTrials.gov registry entry for NCT02747004 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 234 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (15% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Tamoxifen is the first listed.
NCT02747004 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Oost-Vlaanderen, Arizona.
Frequently Asked Questions
What is clinical trial NCT02747004 about?
NCT02747004 is a clinical study titled "A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer". The main purpose of this study is to evaluate the safety and efficacy of abemaciclib plus tamoxifen or abemaciclib alone in women with previously treated hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), metastatic breast cancer.
What is the current status of trial NCT02747004?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 234 participants. The study started on 2016-09-14. Estimated completion is 2026-12.
What conditions does trial NCT02747004 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT02747004?
The interventions under investigation include: Tamoxifen (DRUG), Abemaciclib (DRUG), Prophylactic Loperamide (DRUG).
Who is sponsoring clinical trial NCT02747004?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02747004 being conducted?
This trial has 20 study locations across Arizona, New Hampshire, Tennessee, Texas, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
A Study of Surgery and Radiotherapy in People With Breast Cancer
RECRUITING · Phase 2
-
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.